NCCN Guidelines and HER2-Mutant NSCLC Management

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, review the role of NCCN Guidelines in informing treatment decisions for HER2-mutant non–small cell lung cancer. Dietrich highlights how guideline recommendations help standardize care in a rapidly evolving therapeutic landscape. Leal notes that while guidelines provide a useful framework, clinical judgment remains essential given ongoing data maturation and limited head-to-head comparisons.